Keywords
patient, chronic liver disease, treatment, ademetionine (S-adenosyl-L-methionine), Heptral®.
How to Cite
Shcherbinina, M. (2015). The patient with alcoholic liver disease and depression: theoretical and practical aspects of Heptral® application (medical case). The Practitioner, (1), 14-23. Retrieved from https://plr.com.ua/index.php/journal/article/view/189
Abstract
The article presents an analysis of the clinical management of patients with chronic liver disease and theoretical reasoning of processes taking place at the same time. In the treatment of liver disease, ademetionine (S-adenosyl-L-methionine, trademark Heptral®, Abbott Laboratories SA) was found to be one of the most optimal drugs. The data on the drug based on the results of high-quality experimental and clinical studies, as well as recommendations for the practical use to achieve its maximum efficiency, were presented. In addition to liver disease, the most studied areas of therapeutic use of ademetionine are depression and osteoarthritis.
References
1. Hardy M., Coulter I., Morton S.C. et al. S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Evidence Report/ Technology Assessment Number 64 (Prepared by Southern California Evidence-based Practice Center under Contract No. 290-97-0001). AHRQ Publication No. 02-E034. Rockville, MD: Agency for Healthcare Research and Quality. October 2002. (http://www.ncbi.nlm.nih.gov/books/NBK36942/)
2. Ивашкин В.Т., Маевская М.В. Алкогольно-вирусные заболевания печени. – М.: Литтера, 2007. – 160 с.
3. Краснов B.H., Довженко А.Г., Салтыкова А.Г., Вельтишева Д.Ю., Холмогорова А.Б., Гаранян Н.Г. Организационная модель помощи лицам, страдающим депрессиями, в условиях территориальной поликлиники. Методические рекомендации №2000/107, М3 Российской федерации, Московский НИИ психиатрии, М., 2000; 10-11.
4. Комкова И.И., ЖарковаМ.С., Маевская М.В. Новые направления в изучении алкогольной болезни печени. РЖГГК. 2011; Т.21; №6: 33-41.
5. Mato J.M., Cámara J., Fernández de Paz J. et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999; Jun; 30(6): 1081-9.
6. Bone-Larson C.L., Simpson K.J., Colletti L.M. et al. The role of chemokines in the immunopathology of the liver. Immunol Rev, 2000; 177: 8-20.
7. Tsukamoto H., Lu S.C. Current concepts in the pathogenesis of alcoholic liver injury. FASEBJ. 2001; 15(8): 1335-49.
8. Merrill A.H., Jr, Lingrell S., Wang E. et al. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low-density lipoprotein secretion. J. Biol. Chem. 1995; 270: 13834-41.
9. Lieber C.S. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76(5): 1183S-1187 S.
10. Purohit V., Abdelmalek M.F., Barve S., Benevenga N.J., Halsted C.H., Kaplowitz N. et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007:86 (1): 14-24.
11. Bottiglieri T., Godfrey P., Flynn T. et al. () Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J. Neurol. Neurosurg. Psychiatry, 1990, 53(12): 1096-1098.
12. Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility Journal of Hepatology 2012 v. 57: 1097-1109.
13. Avila M.A., Berasain C., Torres L., Martín-Duce A., Corrales F.J., Yang H., Prieto J. et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatal. 2000;33: 907-14.
14. Mato J.M., Alvarez L., Ortiz et. al. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther., 1997; 73: 265-280.
15. Lee T.D., Sadda M.R., Mendler M.H., Bottiglieri T., Kanel G., Mato J.M. et al. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004;28 (1): 173-181.
2. Ивашкин В.Т., Маевская М.В. Алкогольно-вирусные заболевания печени. – М.: Литтера, 2007. – 160 с.
3. Краснов B.H., Довженко А.Г., Салтыкова А.Г., Вельтишева Д.Ю., Холмогорова А.Б., Гаранян Н.Г. Организационная модель помощи лицам, страдающим депрессиями, в условиях территориальной поликлиники. Методические рекомендации №2000/107, М3 Российской федерации, Московский НИИ психиатрии, М., 2000; 10-11.
4. Комкова И.И., ЖарковаМ.С., Маевская М.В. Новые направления в изучении алкогольной болезни печени. РЖГГК. 2011; Т.21; №6: 33-41.
5. Mato J.M., Cámara J., Fernández de Paz J. et al. S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999; Jun; 30(6): 1081-9.
6. Bone-Larson C.L., Simpson K.J., Colletti L.M. et al. The role of chemokines in the immunopathology of the liver. Immunol Rev, 2000; 177: 8-20.
7. Tsukamoto H., Lu S.C. Current concepts in the pathogenesis of alcoholic liver injury. FASEBJ. 2001; 15(8): 1335-49.
8. Merrill A.H., Jr, Lingrell S., Wang E. et al. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low-density lipoprotein secretion. J. Biol. Chem. 1995; 270: 13834-41.
9. Lieber C.S. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002;76(5): 1183S-1187 S.
10. Purohit V., Abdelmalek M.F., Barve S., Benevenga N.J., Halsted C.H., Kaplowitz N. et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007:86 (1): 14-24.
11. Bottiglieri T., Godfrey P., Flynn T. et al. () Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J. Neurol. Neurosurg. Psychiatry, 1990, 53(12): 1096-1098.
12. Anstee Q.M., Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility Journal of Hepatology 2012 v. 57: 1097-1109.
13. Avila M.A., Berasain C., Torres L., Martín-Duce A., Corrales F.J., Yang H., Prieto J. et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatal. 2000;33: 907-14.
14. Mato J.M., Alvarez L., Ortiz et. al. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther., 1997; 73: 265-280.
15. Lee T.D., Sadda M.R., Mendler M.H., Bottiglieri T., Kanel G., Mato J.M. et al. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004;28 (1): 173-181.
Downloads
Download data is not yet available.